Link copied to clipboard

Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. 

In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.

Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.

To hear about the company’s upcoming 2023, click above.

Explore More

  • Investor Guide: Health & Biotech FY2023
Read MoreHealth

Link copied to clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

"*" indicates required fields

Hidden
Email Lists

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

Featured Companies

  • ASX: PTX Prescient Therapeutics

You might be interested in

Year in Review

Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke

| Stockhead TV

Prepped and Primed

2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner

| Stockhead TV

Health & Biotech

ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow

| Nadine McGrath

Sponsored Articles